

**BIOGRAPHICAL SKETCH**

Provide the following information for the key personnel in the order listed for Form Page 2.  
Follow the sample format on for each person. (See attached sample). **DO NOT EXCEED FOUR PAGES.**

NAME		POSITION TITLE	
Andrea J. Rapkin		Professor, UCLA School of Medicine	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Cornell University, N.Y.	B.A.	1975	Internship, Obstetrics & Gynecology Obstetrics & Gynecology
SUNY University of N.Y. at Buffalo	M.D.	1979-1980	
UCLA School of Medicine, Los Angeles	Residency	1983	

**A. Positions and Honors.****Positions and Employment**

1983 – 1990 Assistant Professor, Dept. of OB-GYN, UCLA School of Medicine  
1983 – 1990 Associate Professor, Dept. of OB-GYN, UCLA School of Medicine  
1997 – Present Professor

**Other Experience and Professional Memberships**

1992 – Present Member, Society for Gynecologic Investigation, International Society for the Study of Psychoneuroendocrinology, American Pain Society, International Pain Society

**B. Selected peer-reviewed publications (in chronological order).**

- Rapkin AJ.** Adhesions and pelvic pain: A retrospective study. *Obstet Gynecol* 1986;68:13-5.
- Rapkin AJ, Edelmuth E, McGuire M.** Whole-blood serotonin in premenstrual syndrome. *Obstet Gynecol* 1987;70:533-7.
- Rapkin AJ, Buckman T, Reading AE, Chang LC.** Platelet monoamine oxidase B activity in women with premenstrual syndrome. *Am J Obstet Gynecol* 1988;159:1536-40.
- Kames LD, **Rapkin AJ, Naliboff BD, Afifi S, Ferrer-Brechner T.** Effectiveness of an interdisciplinary pain management program for the treatment of chronic pelvic pain. *Pain* 1990;41:41-6.
- Rapkin AJ, Kames LD, Darke LL, Stampler F, Naliboff B.** History of physical and sexual abuse in women with chronic pelvic pain. *Obstet Gynecol* 1990;76:92-6.
- Rapkin AJ, Shoupe D, Reading A, Mahesh V.** Decreased opioid tone in PMS: LH response to naloxone. *J Soc Gynecol Invest* 1996;3:93-8.
- Morgan M, **Rapkin AJ, D'Elia L, Reading A, Goldman L.** Cognitive functioning in premenstrual syndrome. *Obstet Gynecol* 1996;88:961-6.
- Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB.** Progesterone metabolite allopregnanolone in women with premenstrual syndrome. *Obstet Gynecol* 1997;90:709-14.
- Rapkin AJ, Cedars M, Morgan M, Goldman L.** Insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in women with premenstrual syndrome. *Fertil Steril* 1998;70:1077-80.
- Rasgon N, McGuire M, Tanavoli S, Fairbanks L, **Rapkin A.** Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. *Fertil Steril* 2000;73:144-149.
- Rapkin AJ, Morgan M, Bonpane C, Martinez-Maza O.** Peritoneal fluid interleukin-6 in women with chronic pelvic pain. *Fertil Steril* 2000;74:325-328.
- Rasgon N, Thomas M, Guze B, Fairbanks L, Yue K, Curran J, **Rapkin A.** Menstrual cycle related neurochemical brain changes using 1H magnetic resonance ('H-MR) spectroscopy in premenopausal women: A pilot study. *Psychiatry Research: Neuroimaging* 2001;106:47-57.

Principal Investigator/Program Director (Last, First, Middle):

13. Freeman EW, Kroll R, **Rapkin A**, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M for the PMS/PMDD research group. Evaluation of a unique oral contraceptive in the treatment of premenstrual Dysphoric Disorder. *J Womens Health Gend Based Med* 2001;10:561-9.
14. Rasgon N, Serra M, Biggio G, Pizu G, Fairbanks L, **Rapkin A**. Neurosteroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual dysphoric disorder. *Eur J Endocrinol* 2001;145:25-33.
15. Rasgon NL, Altshuler LL, Fairbanks LA, Dnkin J, Davtyan C, Elman S, **Rapkin A**. Estrogen replacement therapy (ERT) in the treatment of major depression in perimenopausal women. *J Clin Psychiatry* 2002;63(Suppl 7):45-48.
16. Morgan M, **Rapkin A**. Cognitive flexibility reaction time and attention in women with premenstrual dysphoric disorder. *J Gend Specif Med* 2002;5:28-36.
17. **Rapkin AJ**, Mikacich J, Moatakef-Imani B, Rasgon N. The clinical nature and formal diagnosis of premenstrual, postpartum, and Perimenopausal affective disorders. *Curr Psychiatry Rep* 2002;4:419-428.

### **C. Research Support**

#### **Ongoing Research Support**

Berlex Labs, Inc.

1/01 – 12/03

A Multicenter, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation, Containing Drospirenone, 3mg Ethyl Estradiol 20ug (as Beta-Cyclodextrin Clathrate) in the Treatment of PMDD.

Barr Research, Inc.

2002 – 2003

A Phase III, Randomized, Multicenter, Clinical Trial to Evaluate the Efficacy and Safety of Combination Oral Contraceptive Regimens Utilizing Ethinyl Estradiol During the Pill-Free Interval For Prevention of Pregnancy in Women.

#### **Completed Research Support**

Berlex Labs, Inc.

6/18/99 – 12/18/2000

Validation of the Calendar of Premenstrual Experiences (COPE).

SmithKline Beecham Pharmaceuticals

12/99 – 12/2000

A Double-Blind, Placebo-Controlled, 3-Arm Fixed Dose Study of Paroxetine CR Continuous Treatment (12.5mg and 25MG/day) for Premenstrual Dysphoric Disorder.